GlassScriptPhysician profile
Blas Edward Villa
NPI 1063053072
$6,784.63
in general payments reported to CMS, 2019-2025
24 companies · $1,389 in 2025
The $1,389 reported for 2025 was more than what 91% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $1,228 · 2023: $2,160 · 2024: $1,883 · 2025: $1,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,628 · Travel and Lodging: $753 · Education: $50.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,628.04 |
| Travel and Lodging | $752.59 |
| Education | $50.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $1,095.17 | 2023 | Axonics |
| Janssen Biotech, INC. | $697.42 | 2022-2025 | Tremfya, Stelara |
| Abbvie INC. | $615.30 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $491.18 | 2024-2025 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $490.76 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $487.72 | 2022-2025 | Livdelzi, Vemlidy |
| Lilly USA, LLC | $374.98 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $362.83 | 2022-2024 | Stelara |
| La Jolla Pharmaceutical Company | $294.00 | 2022-2023 | Xacduro |
| E.R. Squibb & Sons, L.L.C. | $246.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $246.81 | 2022-2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2024 | Fasenra |
| Alexion Pharmaceuticals, INC. | $124.99 | 2021 | |
| Madrigal Pharmaceuticals | $124.92 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $124.27 | 2025 | Terlivaz |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $123.81 | 2022 | |
| Aimmune Therapeutics, INC. | $121.82 | 2025 | Zenpep |
| Stryker Corporation | $121.78 | 2025 | Clottriever Bold Catheter |
| Nxstage Medical, INC. | $118.33 | 2024 | |
| Insmed, INC. | $117.64 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.59 | 2023 | Gattex |
| Ferring Pharmaceuticals INC. | $98.75 | 2023 | Rebyota |
| Grifols USA, LLC | $45.97 | 2025 | Prolastin-C Liquid |
| Atricure, INC. | $23.76 | 2025 | Atricure Cryoice Cryosphere Cryoablation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blas Villa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.